Clinical Trial

Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn the overall response rate of giving immunothrapy before surgery in treatment-naive, advanced stage patients with Betal-nut-associated oral cavity cancer. The outcomes to be measured by CT scan are overall response rate of either partial or complete response.
Trial Details
NCT Number NCT07733466
Lead Sponsor Peter Brett, MD
Conditions Betel-nut-associated Oral Carcinoma
Enrollment 20 participants
Start Date 2026-08-15
Primary Completion 2030-07 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-10